Havrix
GlaxoSmithKline
- Authorized for cohorts 12 months +.
- Pediatric: 720 ELISA units / 0.5 mL.
- Adult: 1440 ELISA units / 1.0 mL.
- Interval: 2-dose series (6-12 months).
Registry Index
Updated Jan 5, 2026Clinical Standard
Vaccine Safety Registry
Hepatitis A Vaccine Safety
Professional safety data on Hepatitis A vaccines. Clinical trial outcomes, manufacturer formulations (Havrix, Vaqta), and long-term surveillance metadata.
Clinical Overview
Professional summary
Hepatitis A is a significant liver disease induced by the Hepatitis A Virus (HAV). HAV transmission occurs primarily through the fecal-oral route, often via contaminated water or food modules.
Pathology ranges from mild, self-limiting illness to severe clinical hepatic failure lasting several months. While pediatric cohorts may present as asymptomatic, they serve as critical nodes for viral transmission.
Hepatitis A vaccine is a safe, effective tool for preventing HAV-induced hepatic pathology.
The vaccine is highly effective in preventing both individual disease and community outbreaks.
Routine pediatric vaccination is recommended starting at 12-23 months of age.
Two-dose series ensures durable long-term immunological memory.
Available Registry Modules
Vaccine modules
Vaqta
Merck & Co.
- Authorized for cohorts 12 months +.
- Pediatric: 25 units / 0.5 mL.
- Adult: 50 units / 1.0 mL.
- Interval: 2-dose series (6-18 months).
View detailed composition and titration analysis on official nodes.
Eligibility & Schedules
Protocol triage
Routine Protocol
- Pediatric cohorts (12-23 months)
- Catch-up immunization (2-18 years)
High-Risk Adult Triage
- International travelers to endemic zones
- Men who have sex with men (MSM)
- Illicit drug users (injection/non-injection)
- Chronic liver disease patients
Contraindications
- Hypersensitivity to previous Hepatitis A dose
- Acute moderate-to-severe febrile illness
- Known allergies to registry module components
Adverse Reaction Profile
Expected and critical events
Local Reactions
- Injection site pain
- Localized erythema
- Induration (Swelling)
Systemic Profile
- Generalized fatigue
- Cephalalgia (Headache)
- Low-grade pyrexia
- Anorexia (Loss of appetite)
Emergency Protocol
Severe anaphylaxis is statistically exceptional. Seek intervention for angioedema, respiratory distress, urticaria, or tachycardia.
Safety Metadata Analysis
Monitoring summary
1995
Registry Entry
25+ Years
Surveillance Data
Millions
Doses Synchronized
Institutional Surveillance
Decades of VAERS data and active surveillance studies confirm an exemplary safety profile across all global recommended cohorts.
Verified Source: CDC / WHO
Last global review: September 1, 2025. Content verified by HCP Connect clinical editorial staff in alignment with 2026 safety protocols.